SIC 2835 – In Vitro and In Vivo Diagnostic Substances
Valuation | |
---|---|
Market Cap ($M) | 15.07 |
Enterprise Value ($M) | 14.16 |
Book Value ($M) | 2.96 |
Book Value / Share | 0.14 |
Price / Book | 5.09 |
NCAV ($M) | 1.26 |
NCAV / Share | 0.06 |
Price / NCAV | 11.95 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -1.99 |
Return on Assets (ROA) | -0.98 |
Return on Equity (ROE) | -2.45 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 3.29 |
Current Ratio | 3.29 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 2.77 |
Assets | 4.46 |
Liabilities | 1.50 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.02 |
Operating Income | -7.24 |
Net Income | -8.38 |
Earnings Per Shares Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -5.67 |
Cash from Investing | -0.79 |
Cash from Financing | 3.63 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G | BlackRock Inc. | 5.20 | ||
13D/A | Philibert Robert | 19.10 | -25.51 | |
13D/A | Dogan Meeshanthini | 20.90 | -86.47 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
35,216 | 123,008 | 28.63 | |
91,711 | 43,599 | 210.35 | |
94,251 | 46,511 | 202.64 | |
92,290 | 47,012 | 196.31 | |
(click for more detail) |
Similar Companies | |
---|---|
CALC – CalciMedica, Inc. | CAPR – Capricor Therapeutics, Inc. |
CASI – CASI Pharmaceuticals, Inc. | CDMO – Avid Bioservices, Inc. |
CDTX – Cidara Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io